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Aims Inﬂuenza A virus (IAV) infection markedly up-regulates ectopic trypsins in various organs, viral envelope glycoprotein
processing proteases, which are pre-requisites for virus entry and multiplication. We investigated the pathological
roles of trypsin up-regulation in the progression of IAV-induced myocarditis, cytokine induction, and viral replication
in the hearts, and also investigated the protective effects of trypsin inhibitor on cardiac dysfunction in vivo and selec-
tive knockdown of trypsin on IAV-induced cellular damage in cardiomyoblasts.
Methods
and results
The relationship of the expression among IAV RNA, trypsins, matrix metalloproteinase (MMP)-9, MMP-2, pro-
inﬂammatory cytokines interleukin (IL)-6, IL-1b, and tumour necrosis factor-a was analysed in mice hearts and
cardiomyoblasts after IAV infection. The severity of myocarditis was most noticeable during Day 6–9 post-infection,
along with peak expression of viral RNA, trypsins, particularly trypsin2, MMPs, and cytokines. Cardiac ATP levels were
the lowest at Day 9.Up-regulated trypsins,viralprotein,and tissue-injuredlociin the myocardiumwere closely localized.
Trypsininhibitoraprotinintreatmentinvivoandselectivetrypsin1-andtrypsin2-knockdown,particularlythelatter,inH9c2
cardiomyoblasts signiﬁcantly suppressed viral replication, up-regulation of MMPs, and production of active MMP-9 and
cytokines, resulting in marked protection against cellular damage, ATP depletion, and apoptosis. IAV infection-induced
cardiac dysfunction monitored by echocardiography was improved signiﬁcantly by aprotinin treatment.
Conclusions IAV-induced trypsins, particularly trypsin2, in the myocardium trigger acute viral myocarditis through stimulation of
IAV replication, proMMP-9 activation, and cytokine induction. These results suggest that up-regulation of trypsins
is one of the key host pathological ﬁndings in IAV-induced myocarditis.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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1. Introduction
Inﬂuenza A virus (IAV) is the most common infectious pathogen in
humans, causing signiﬁcant morbidity and mortality in infants and the
elderly.
1,2 Severe inﬂuenza causes pneumonia and sometimes cardiac
complications, such as myocarditis and acute myocardial infarction.
3,4
In addition, people with underlying chronic cardiovascular diseases
are particularly at high risk of IAV-induced myocardial diseases.
5
IAV initially infects the respiratory mucosal surface and induces
various host cellular factors other than anti-viral immunoglobulins,
not only in the airway but also in other organs, such as pro-
inﬂammatory cytokines, matrix metalloproteinases (MMPs), and
ectopic trypsins, viral envelope haemagglutinin (HA) processing pro-
teases. Among these factors, ectopic trypsins are crucial for viral
entry, replication, and spread, because IAV has no HA processing pro-
tease in its genes and post-transcriptional HA cleavage by cellular
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entry into cells.
6–8 However, the inter-relationship among these
factors in the progress of IAV-induced myocarditis in severe inﬂuenza
remains unclear.
Pro-inﬂammatory cytokines, tumour necrosis factor (TNF)-a, inter-
leukin (IL)-1b and IL-6 mediate cardiac injuries through recruitment of
immune cells towards inﬂammatory loci, and enhance the production
of MMPs at the transcriptional level via nuclear factor-kappa B and
activator protein 1.
9,10 In addition, these cytokines increase nitric
oxide production in the heart.
11 Over production of nitric oxide is
followed by myocardial ATP depletion through inhibition of the
activity of mitochondrial enzymes complex I and complex II and
induction of cardiomyocyte apoptosis by changing the cellular
balance between Bak and Bcl-x.
12,13 Induced active MMPs, such as
MMP-2 and MMP-9, promote endothelial hyperpermeability and
assist inﬂammatory cell migration through the breakdown of vascular
basement membranes and extracellular matrix (ECM).
14 Destruction
of ECM further causes cardiomyocyte anoikis/apoptosis,
15 resulting in
cardiac dilation and dysfunction. The induced MMP-2 and MMP-9 in
turn activate pro-inﬂammatory cytokines into their active forms.
16,17
Exaggerated expression and activation of MMPs and cytokines result
in severe tissue injury.
We previously reported that IAV infection signiﬁcantly up-regulates
ectopic trypsins in the brain endothelial cells and hippocampal
neurons,
7 which may potentiate brain vascular hyperpermeability,
18
viral spread, and tissue damage. Since trypsins efﬁciently convert
proMMPstoactive MMPs,
19,20inductionoftrypsinsandproMMPssyner-
gisticallydegradesvascularbasementmembranesandECM.Furthermore,
up-regulated trypsins in turn evoke cytokine release via proteinase-
activated receptor (PAR)-2.
21 These results suggest close interaction
among IAV, proteases, and cytokines in the pathogenesis of severe inﬂu-
enza. Trypsin has three major isoforms; trypsin1 (cationic trypsin, T1),
trypsin2 (anionic trypsin, T2), and trypsin3 (mesotrypsin, T3).
22
The aim of the present study was to clarify the pathological roles of
up-regulated trypsins in the progression of myocarditis in severe inﬂu-
enza. The results ﬁrst deﬁned the pivotal roles of up-regulated tryp-
sins in viral replication, proMMP-9 activation, and cytokine induction
in IAV-induced myocarditis. The results also presented the thera-
peutic effects of trypsin inhibition on IAV-induced myocarditis.
2. Methods
2.1 Inﬂuenza myocarditis model
This study conforms to the Guide for the Care and Use of Laboratory
Animals (NIH Publication No. 85-23, 1996) and was approved by the
animal care committee of the University of Tokushima. Speciﬁc pathogen-
free 8-week-old male BALB/c mice (SLC, Japan) were infected intra-
nasally with 40 plaque-forming units (PFU) IAV/PR/8/34(H1N1), about
one-third of a minimum lethal dose, in 15 mL of saline or saline as a
vehicle under ketamine anaesthesia. Mice were euthanized at Day 0, 3,
6, 9, or 12 post-instillation. To analyse the effects of trypsin inhibition,
trypsin inhibitor aprotinin (Sigma) was injected intra-peritoneally at
2 mg/kg twice daily immediately after infection for 9 days.
2.2 Haemodynamic measurements
Mouse blood pressure and heart rate were assessed by a blood pressure
monitor MK-1030 (Muromachi Kikai). Echocardiograph was performed
with a 12 MHz transducer on an Aplio 80 ultrasound machine (Toshiba
Medical Systems) under the awake state of mice at Day 9 post-infection.
Left ventricular M-mode echocardiogram was obtained from parasternal
short-axis view in the left lateral decubitus position. Left ventricular end-
diastolic dimension (LVEDD), left ventricular end-systolic dimension
(LVESD), and per cent fractional shortening (%FS), which was calculated
by the formula [(LVEDD2LVESD)/LVEDD]×100, were measured from
three consecutive cycles and averaged. Stroke volume (SV) and cardiac
output (CO) were also analysed as described in Supplementary material
online.
2.3 Tissue preparation
Mice were divided randomly into two groups before tissue preparation.
Hearts of 10 mice in the ﬁrst group were weighed immediately after prep-
aration and then weighed again after drying for 3 days at 708C to obtain
wet/dry weight ratios. Ten mice in the second group were injected intra-
peritoneally with 200 mL of 2% Evan’s blue solution in saline at 3 h before
tissue preparation to analyse vascular permeability and injured loci. Iso-
lated heart of each animal was cut into halves; one-half was ﬁxed with
4% paraformaldehyde for histopathological evaluation, and the other
half was stored at 2808C for biochemical analyses. All experiments
were repeated at least thrice to ensure reproducibility.
2.4 Cell culture, transfection, and infection
Cardiomyoblast H9c2 cells (ATCC) were cultured in Dulbecco’s modiﬁed
Eagle’s medium (DMEM) containing 10% fetal calf serum (FCS), 100 units/
mL penicillin/streptomycin, and 2 mM L-glutamine (growth medium). For
gene-silencing experiments, trypsin1-shRNA plasmid (T1-sh), trypsin2-
shRNA plasmid (T2-sh), control-shRNA plasmid (C-sh), transfection
reagents, and medium were purchased from Santa Cruz. Cells in 6-well
tissue culture plate (50–70% conﬂuence) were washed with transfection
medium, and incubated with 1 mg shRNA plasmid and 3 mL of transfection
reagent in 1 mL transfection medium per well for 7 h at 378C, then sup-
plemented with 1 mL of DMEM containing 20% FCS for 24 h according to
the protocol recommended by the manufacturer. Thereafter, the trans-
fection mix was replaced by fresh growth medium. Puromycin-resistant
H9c2 cell colonies were selected for 3 weeks after transient transfection
for 48 h, and then propagated to establish stable transfectant T1-sh, T2-sh,
and C-sh cell lines. After washing twice with Ca
2+- and Mg
2+-free
phosphate-buffered saline, these cells in serum-free medium sup-
plemented with ITS premix (BD Biosciences) were infected with IAV/
PR/8 at multiplicity of infection (m.o.i.) 1 or mock infected for 24 h.
2.5 Reverse transcription polymerase chain
reaction (RT-PCR)
Total RNA was extracted with RNeasy Mini kit (Qiagen), and reverse
transcribed using oligo primers and universal primers in SuperScript III
RT kit (Gibco BRL) for cDNAsynthesis. The primer pairs used to
amplify trypsins and IAV non-structure protein 1 (NS1) gene segment,
and methods of RT-PCR are described in Supplemental material online.
PCR products were analysed by agarose gel electrophoresis and visualized
by treatment with ethidium bromide.
2.6 Immunoblotting and gelatin zymography
Tissues were homogenized with three volumes of 0.05 M Tris-HCl, (pH
7.6), containing 2% SDS and 0.5 M NaCl. Cultured cells were lysed with
RIPA lysis buffer (Santa Cruz). Extracts were concentrated by Amicon
Ultra 10K device (Millipore) by centrifugation. Immunoblotting and zymo-
graphy were performed as described previously.
7 Target proteins were
reacted with their speciﬁc antibodies against trypsin, MMP-9 and MMP-2
(Santa Cruz), TNF-a (R&D system), IL-6 and IL-1b (Sigma), actin (Chemi-
con), and IAV (Takara). Immunoreactive bands were visualized by
enhanced chemiluminescence detection system (Amersham). For gelatin
zymography, the extracts (30 mg protein) were subjected to electrophor-
esis on 10% gelatin zymogram gels (Invitrogen).
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Immunohistochemistry of up-regulated trypsin(s) in the myocardium was
performed as described previously.
7 Brieﬂy, after blocking endogenous per-
oxidase activity with 3% H2O2 and non-speciﬁc binding sites with goat
serum, sections were incubated with rabbit anti-trypsin antibody (Santa
Cruz). Immuno-deposits were visualized by using the avidin–biotin–peroxi-
dase kit (Vector). For double staining, rabbit anti-trypsin and mouse
anti-IAV (Takara) antibodies were used for the initial reaction and immuno-
deposits of trypsins and IAV in the hearts were visualized by goat anti-rabbit
Alexa Fluor 647 conjugated secondary antibody (Molecular Probes) and
goat anti-mouse ﬂuorescein isothiocyanate-conjugated secondary antibody
(Sigma), respectively. IAV-infected H9c2 cells were detected with rabbit
anti-IAV polyclonal antibodies, followed by goat anti-rabbit Texas red-
conjugated secondary antibody (Molecular Probes). Nuclei were stained
blue by 4,6-diamidino-2-phenylindole (DAPI) (Dojindo).
2.8 Measurement of mitochondrial membrane
potential and apoptosis
Mitochondrial membrane potential (△Cm) was analysed by the APO
LOGIX
TM JC-1 assay kit (Bachem) as described previously.
23 Brieﬂy,
cells were incubated with 10 mM JC-1 dye for 15 min at 378C in darkness
and immediately imaged after washing. Apoptosis was detected by the In
situ cell death detection kit, ﬂuorescein (Roche) according to the protocol
offered by the manufacturer.
2.9 ATP level and enzyme-linked
immunosorbent assay (ELISA)
ATP in the heart homogenates was extracted with extraction solution in
the XL-ATP kit (APRO) according to the protocol offered by the
manufacturer. ATP in cultured cells was extracted with 1% trichloroacetic
acid after trypsinization for cell count, followed by centrifugation. Result-
ing supernatants were neutralized with 1 M Tris-acetate buffer, (pH 7.5),
as described previously.
23 ATP levels in these extracts were measured by
ENLITEM
w ATP assay system bioluminescence detection kit (Promega)
and normalized relative to the protein concentrations or cell numbers.
The levels of IL-6, IL-1b, and TNF-a in the culture medium were
measured by ELISA kits (R&D system).
2.10 Statistical analysis
Resultsarepresentedasmean+SD.Signiﬁcancewascalculatedbyone-way
ANOVA. A P value of ,0.05 was considered statistically signiﬁcant.
3. Results
3.1 Increased vascular permeability, tissue
oedema, and inﬂammatory cell inﬁltration
in acute inﬂuenza myocarditis
Mice intra-nasally inoculated with 40 PFU of IAV/PR/8(H1N1) exhib-
ited acute myocarditis, as conﬁrmed by histological examination of
haematoxylin and eosin-stained sections. Inﬂammatory inﬁltrates
appeared initially in the subepicardium at Day 3 post-infection, fol-
lowed by extensive inﬁltration across the interstitium and perivascular
areas deep into the myocardium, accompanied by ECM destruction
during Day 6 and 9, and then alleviated at Day 12 (Figure 1A–C). Cor-
onary vascular permeability monitored by Evan’s blue extravasation
and tissue oedema by wet/dry weight ratio started to increase at
Figure 1 Increased vascular hyperpermeability, tissue oedema, and inﬂammatory cell inﬁltration in acute myocarditis, and kinetics of up-regulation
of trypsins in myocardium after IAV infection. Vascular hyperpermeability monitored by Evan’s blue extravasation during the course of infection from
Day 0 (d 0) to 12 (d 12) (A). Haematoxylin and eosin staining (B). Bar ¼ 50 mm. Heart oedema determined by wet/dry weight ratio (C). Data are
mean+SD of 10 mice in each group. **P , 0.01 vs. D 0;
††P , 0.01 vs. D 9. Detection by RT-PCR of trypsin1–3, trypsin isoforms T1,T 2, and T3
and IAV NS1 gene in the hearts from Day 0 to 12 post-infection (D1, E, and F1, respectively). Detection by zymography of trypsin activity (D2),
by western immunoblotting of trypsinogen and trypsin (D3) and viral nucleoprotein (NP) (F2). Each result is a representative of three experiments.
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decreased signiﬁcantly at Day 12.
3.2 Up-regulation of trypsins by IAV
infection in myocardium and close
distribution of trypsins with viral antigen
and inﬂammatory injury
InfectionofIAV/PR/8(H1N1)begantoup-regulatetrypsins(T1–3)i nt h e
heartsat Day3post-infection,reachedapeakat Day6,remainedat high
levelsuntilDay9,andthenstartedtodecreaseatDay12(Figure1D).The
majorities of up-regulated T1–3 were trypsinogens, as determined by
westernimmunoblotting,andwerepartiallyconvertedtoactivetrypsins
withapeakatDay6monitoredbyzymography.Amongthethreetrypsin
isoforms in murine hearts without infection at Day 0, T2 was the predo-
minant isoform and the level of T1 was less than that of T2, while T3 was
barely detected. After infection, T2 was predominantly induced with a
peak during Day 6 and 9 (Figure 1E). The viral levels in the hearts mon-
itored by the NS1 gene and nucleoprotein (NP) showed that it also
peaked at Day 6 and started to decrease at Day 9 (Figure 1F). Immuno-
histochemical analysis revealed that the up-regulated trypsins were dis-
tributed in the myocardium of infected loci and inﬂammatory
inﬁltrates in the peripheral infected loci, which were most obvious at
Day 6 after infection (Figure 2A). Fluorescent analyses of trypsins and
viral protein as well as Evan’s blue dye, a marker of hyperpermeability
and tissue injury, showed their overlapped localization, suggesting their
close correlation at infected foci (Figure 2B).
3.3 Up-regulation of MMPs and cytokines
with cardiac fuel depletion after IAV
infection
Limited amounts of trypsin(s) effectively converts various proMMPs,
particularly proMMP-9, into active MMPs
19 and the latter in turn
convert pro-inﬂammatory cytokines to active cytokines,
16,17 resulting
in cardiomyocyte injury and ECM degradation.
16 The relationship
among trypsin up-regulation, MMP activation, and cytokine induction
was analysed in IAV-induced myocarditis. Along with an increase in
trypsin levels, up-regulated proMMP-9 was readily converted to
active MMP-9 (actMMP-9) from Day 3 post-infection, whereas
up-regulated proMMP-2 was not (Figure 2C). The actMMP-9 levels
increased to a peak value during Day 6 and 9, followed by a decrease
in the levels at Day 12. Similar time courses of induction of the cyto-
kines IL-6, IL-1b, and TNF-a, which are activated by MMPs,
16,17 were
Figure 2 Close distribution of up-regulated trypsins with viral antigen and inﬂammatory injury, and kinetics of up-regulation of MMPs and cytokines as
well as ATP depletion in the hearts after IAV infection. (A) Immunohistochemical detection of up-regulated trypsins in the myocardium from Day 0 (d 0)
to 12 (d 12) post-infection. Bar ¼ 50 mm. (B) Immunoﬂuorescence detection of viral antigen (green), trypsins (blue), and injured loci monitored by
Evan’s blue extravasation (red) in the hearts at Day 0 and 6. Bar ¼ 50 mm. Right panel shows merge. (C) Kinetics of up-regulation of proMMP-9,
proMMP-2, and actMMP-9 in the hearts determined by zymography (C1) and western immunoblotting (C2) from Day 0 to 12 post-infection. (D) Kinetics
of up-regulation of IL-6, IL-1b, and TNF-a in the hearts determined by western immunoblotting from Day 0 to 12 post-infection. (E) Changes in cardiac
ATP levels during IAV infection. Data are mean+SD of three repeated experiments from 10 mice per each group. *P,0.05, **P , 0.01 vs. Day 0;
†P , 0.05 vs. Day 9.
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the hearts. Intraperitoneal administration of aprotinin (Apr) at 2 mg/kg twice a day for 9 days signiﬁcantly suppressed viral replication and trypsin
up-regulation analysed by RT-PCR (A1 and B), by western immunoblotting (A2), and zymography (A3), up-regulation of proMMP-9, actMMP-9,
proMMP-2, IL-6, IL-1b, and TNF-a analysed by western immunoblotting (C1) and ATP depletion (D) at Day 9 post-infection. b-Actin as an internal
control. Relative levels of MMPs and cytokines after IAV infection vs. mock infection (C2 and C3). *P , 0.05, **P , 0.01 vs. mock infection.
†P , 0.05,
††P , 0.01 vs. IAV infection without Apr treatment.
Figure 4 Suppression of cardiac function by IAV infection and its restoration by trypsin inhibitor. Representative M-mode echocardiogram images of
mice infected with mock and IAV with or without intraperitoneal administration of aptrotinin (Apr) at 2 mg/kg twice a day for 9 days (A1). Measure-
ments of LVEDD and LVESD at Day 9 post-infection (A2) and %FS (A3). Comparison of blood pressure (B) and heart rate (C) at Day 9 post-infection
among mock and IAV-infected mice treated with or without Apr. SBP, systolic blood pressure; DBP, diastolic blood pressure. *P , 0.05, **P , 0.01 vs.
mock infection;
††P , 0.01 vs. IAV infection without Apr treatment.
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the hearts (Figure 2E). ATP levels were decreased after viral infection
with a valley at Day 9 and then started to recover at Day 12. Increase
in the viral load for infection up-regulated trypsin(s) and depleted ATP
in the hearts in a dose-dependent manner at Day 6 post-infection
(see Supplementary material online, Figure S1).
3.4 Administration of trypsin inhibitor
suppressed viral replication and
up-regulation of trypsins, MMPs, and
cytokines as well as ATP depletion, and
signiﬁcantly improved cardiac function
Administration oftrypsin inhibitoraprotininimmediatelyafter IAV infec-
tion at 2 mg/kg twice a day for 9 days markedly suppressed IAV replica-
tion monitored by NS1 gene and NP (Figure 3A). Up-regulation by IAV
infection of trypsin isoforms and T1–3 monitored by RT-PCR,
up-regulation of trypsinogens, trypsins, proMMPs, actMMP-9 as well as
the cytokines IL-6, IL-1b, and TNF-a, analysed by western immunoblot-
ting, and trypsin activity monitored by zymography were signiﬁcantly
inhibited by aprotinin administration at Day 9 post-infection
(Figure 3A–C). Depleted cardiac ATP levels were improved by aprotinin
treatment (Figure 3D). Suppression of cardiac function by IAV infection
monitored by echocardiographic evaluation, blood pressure, and heart
rate at Day 9 post-infection was evident (Figure 4). Left ventricular
function monitored by LVESD values and%FS as well as SV and CO
(see Supplementary material online, Table S1) was signiﬁcantly sup-
pressed after infection, although LVEDD values were in a similar range
betweenmockandIAV-infectedmice.LowCObyIAVinfectionresulted
in low blood pressure and compensatory tachycardia. The cardiac
dysfunction was improved signiﬁcantly by aprotinin with the increase
in the values of%FS, SV, CO, and blood pressure aswell asthe decrease
in the values of LVESD and heart rate.
3.5 IAV infection up-regulated trypsins and
MMPs in cultured cardiomyoblasts with
ATP depletion
IAV replication monitored by NS1 gene and NP was also observed in
H9c2cardiomyoblastsafterinfectionfor24 hatm.o.i.1(seeSupplemen-
tary material online, Figure S2A–B). Up-regulation of trypsinogens,
Figure 5 Effects of trypsin knockdown on IAV replication, MMPs up-regulation, and actMMP-9 production in H9c2 cardiomyoblasts. Silence efﬁ-
ciency of T1 and T2 genes was determined by RT-PCR in T1-sh, T2-sh, and C-sh cell lines (A). Effects of T1- and T2-knockdown on viral replication
monitored by NS1 gene in cell lysate by RT-PCR, NP in culture media by western Immunoblotting (B1), and relative values of NS1 and NP vs. infection
control (C-sh) (B2). Immunoﬂuorescent detection of viral antigen (red) in H9c2 cells (C1) at 24 h post-infection. Nuclei were stained by DAPI.
Bar ¼ 25 mm. Percentage of infected cells (C2). Data are mean+SD of three independent experiments. Effects of T1- and T2-knockdown on the
expression of proMMP-9, proMMP-2, and actMMP-9 in cell lysate and culture medium of T1-sh, T2-sh, and C-sh cells infected with IAV or mock mon-
itored by western immunoblotting (D). *P , 0.05, **P , 0.01 vs. mock infection;
††P , 0.01 vs. infection control;
##P , 0.01 vs. T1-knockdown.
H.-Y. Pan et al. 600trypsins,andproMMPsbyIAVinfectionwasconﬁrmedinH9c2cells(see
Supplementary material online, Figure S3). Among the trypsin isoforms,
T2 was dominant while T3 was detected in a trace amount, in a similar
manner in the hearts. IAV up-regulated precursor forms of proteases,
such as trypsinogens, proMMP-9, and proMMP-2, in the cell lysate,
while IAV-induced mature forms of proteases, such as trypsins and
actMMP-9, in the culture medium. Treatment of the cells with 1.5 mM
aprotinin effectively inhibited IAV replication and up-regulation of pro-
teases, particularly the production of actMMP-9. These results indicate
that secreted trypsins readily promote IAV replication and convert
proMMP-9 to actMMP-9 in extracellular milieu. Increase in the viral
load up-regulated trypsins in the culture medium and depleted ATP in
H9c2 cells in a dose-dependent manner (see Supplementary material
online, Figure S4). In neonatal heart cells, accumulated viral antigens
(red) were detected after IAV infection not only in cardiomyocytes
identiﬁed by cardiac myosin (green) but also in non-myocytes
(see Supplementary material online, Figure S5).
3.6 Trypsin knockdown suppressed viral
replication and production of active MMP-9
and cytokines
Since host cellular trypsins trigger IAV entry and viral replication in
target cells,
6–8 we analysed the effects of silencing major trypsin
genes, T1 and T2, on viral replication and production of actMMP-9
and cytokines in stable transfectant T1-sh, T2-sh, and C-sh H9c2
cell lines. Expressions of T1 and T2 genes determined by RT-PCR
were selectively and signiﬁcantly suppressed in T1-sh and T2-sh
cells, respectively, in comparison with the levels in control (C-sh)
cells (Figure 5A). Viral replication monitored by the NS1 gene
and the levels of NP showed signiﬁcant suppression of IAV
replication in T1- and T2-knockdown cells, the suppression efﬁciency
being signiﬁcantly higher in T2-knockdown than in T1-knockdown
(Figure 5B1–2). Signiﬁcant reduction in the number of
immunoﬂuorescence-labelled viral antigen in the infected cells
(red) was detected under T1-a n dT 2-knockdown conditions, par-
ticularly T2-knockdown condition, compared with those in C-sh
cells (Figure 5C1–2).
Up-regulation of both proMMP-9 and proMMP-2 was detected in
C-sh cells after infection in a similar manner in vivo, and the
up-regulation was signiﬁcantly suppressed by T1-a n dT 2-knockdown,
the suppression efﬁciency in T2-knockdown being higher than in
T1-knockdown (Figure 5D and Supplementary material online, Figure
S6A). Signiﬁcant suppression of actMMP-9 production monitored by
the ratio of actMMP-9/proMMP-9 was observed in the culture
medium of T1-a n dT 2-knockdown cells, the efﬁciency in T2-knockdown
b e i n gh i g h e rt h a ni nT 1-knockdown (Figure 5D and Supplementary
material online, Figure S6B).
Figure 6 IAV infection-induced cytokine up-regulation, mitochondrial membrane depolarization, ATP depletion and apoptosis, and abrogation by
T1- and T2-knockdown in H9c2 cardiomyoblasts. Effects of T1- and T2-knockdown on IL-6, IL-1b, and TNF-a levels in culture medium were analysed
by ELISA at 24 h post-infection (A). △Cm of C-sh, T1-sh, and T2-sh cells infected with mock or IAV were analysed after IAV infection for 24 h (B). Top:
△Cm was monitored by treatment for 15 min with JC-1 (red). Bottom: apoptotic cells detected by TUNEL staining (light blue). Nuclei were stained by
DAPI. Bar ¼ 25 mm. Right: percentage of apoptotic cells in total cells. ATP levels under the same experimental conditions in B (C). Data are
mean+SD of three independent experiments. *P , 0.05, **P , 0.01 vs. mock infection;
†P , 0.05,
††P , 0.01 vs. infection control;
#P , 0.05,
##P , 0.01 vs. T1-knockdown.
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cytokine up-regulation, mitochondrial
membrane potential, ATP levels, and
apoptosis in cardiomyoblasts
Induction of pro-inﬂammatory cytokines by IAV infection in the
culture medium, such as IL-6, IL-1b, and TNF-a, were suppressed
under T1- and T2-knockdown conditions, particularly IL-6 in
T2-knockdown (Figure 6A). We further analysed the effects of
trypsin knockdown on △Cm, intracellular ATP levels
23,24 and apopto-
sis after IAV infection for 24 h. Active mitochondria with high △Cm
appeared red by cationic lipophilic probe JC-1
23 as shown in the
cells with mock infection (Figure 6B, C-sh, mock). Viral infection mark-
edly reduced the red ﬂuorescence indicating mitochondrial depolariz-
ation and reduction of △Cm.T 1- and T2-knockdown, particularly
T2-knockdown, improved the infection-induced mitochondrial
depolarization (Figure 6B,T 2-sh, infection). The numbers of apoptotic
cells analysed by TUNEL staining were signiﬁcantly reduced under
T1- and T2-knockdown conditions, particularly T2-knockdown con-
dition. ATP levels in H9c2 cells were reduced to about 61% after
the viral infection, and this reduction was abrogated by trypsin-
knockdown, particularly T2-knockdown (Figure 6C ).
4. Discussion
The present study reported several new observations: (i) IAV infec-
tion up-regulated ectopic trypsins, particularly T2 among the three
isoforms, MMPs, and cytokines, and also induced ATP depletion in
the heart in vivo and also cardiomyoblasts in vitro. (ii) Administration
of trypsin inhibitor aprotinin suppressed viral replication,
up-regulation of trypsins, MMPs, and cytokines as well as ATP
depletion, and signiﬁcantly improved cardiac function. (iii) Trypsin-
knockdown, particularly T2-knockdown, in cardiomyoblasts effectively
suppressed IAV replication and ATP depletion accompanied by the
protection against mitochondrial membrane de-polarization and
apoptosis.
Inﬂuenza is a recognized cause of myocarditis and acute myocardial
infarction, which can lead to signiﬁcant impairment of cardiac function
and mortality.
4,25 However, the pathogenesis of myocarditis has not
been fully clariﬁed. We elucidated here the crucial roles of inducible
and ectopic host cellular trypsins in the pathogenesis of IAV
infection-induced acute myocarditis and found that aprotinin adminis-
tration and selective trypsin-knockdown effectively suppress
up-regulation of cellular pathogenic factors induced by IAV infection,
such as trypsins, MMPs, and cytokines, resulting in the improved
cardiac function.
Binding sites of nuclear factor-kappa B and activator protein 1 are
found in the promoter regions of T1 and T2 and these transcrip-
tional factors up-regulate trypsin expression (Talukder SR et al.,
manuscript in preparation) in a similar manner to MMP-9 up-
regulation.
9,10 These data suggest that IL-6, IL-1b, and TNF-a,
which induce these transcriptional factors, may play important
roles in up-regulation of both trypsins and MMP-9. Trypsins are
secreted as trypsinogens and readily converted to trypsins through
auto-activation or by widely distributed endogenous activators.
26,27
Trypsins proteolytically trigger various cellular events such as acti-
vation of proMMPs
18,19 and pro-urokinase.
28 Trypsins also
promote IAV entry and replication,
6,8 intracellular signal transduc-
tion, and release of cytokines through PAR-2.
21,29 Close distribution
of inﬂuenza virus antigens, up-regulated trypsins, inﬂammatory inﬁl-
trates in injured heart loci indicates a mutual close-relationship
among these pathogenic factors.
MMP-2 and MMP-9 are type IV collagenases and MMP-9 also
digests type I and III collagens while MMP-2 does not.
30 IAV infection
up-regulated both proMMP-2 and proMMP-9 in the myocardium and
cardiomyoblasts, with only marked proMMP-9 activation, but not
proMMP-2, probably because proMMP-9, but not proMMP-2, is
readily activated by induced trypsins.
31
Although both T1- and T2-knockdown protected cardiomyoblasts
against damage during IAV infection, the protective effects of T2-
-knockdown were more efﬁcient than those of T1-knockdown. The
difference might be explained by the following reasons: (i) Abundance
of T2 at nearly double the amount of T1 in cardiac tissue and cardio-
myoblasts. (ii) T2 activates proMMP-9 efﬁciently even at a molar ratio
of 1:1000, the lowest concentrations reported so far for any
proMMP-9 activators.
32 (iii) T2 also degrades type I collagen and
serves as an efﬁcient activator of a pro-urokinase cascade and pro-
collagenases MMP-1,-8, and -13,
33 and thus may cause an even more
serious tissue destruction.
To date, there are no effective therapies for IAV infection-induced
myocarditis apart from anti-viral drugs and symptomatic treatments.
Previous studies indicated that inhibition of cytokine production and
MMP-9 activity has protective effects on myocarditis.
34,35 However,
recent studies showed that MMP-9-deﬁcient mice display reduced
recruitment of leucocytes to the infected sites, resulting in impaired
host defence and enhanced dissemination of the infection.
36,37 Our
present data suggest that administration of the trypsin inhibitor apro-
tinin and selective trypsin knockdown suppress IAV multiplication by
intercepting the interrelationship among IAV replication, up-regulation
of trypsins, MMPs, and cytokines, and also suppress ATP depletion
and apoptosis in the myocardium and cardiomyoblasts. In addition,
aprotinin administration improved heart function, monitored by
LVESD, %FS, SV, CO, blood pressure, and heart rate. We are cur-
rently investigating the therapeutic effects of various trypsin inhibitors
other than aprotinin on IAV infection-induced acute myocarditis in
vivo. In conclusion, the presented data demonstrated that up-regulated
trypsin, particularly T2, is one of the key pathogenic host factors in IAV
infection-induced myocarditis.
Supplementary material
Supplementary material is available at Cardiovascular Research online.
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